Neurotune Strengthens Management
Neurotune AG announced personnel changes in its board of directors as well as management. Dr. Raimund Eckel will form the Board of Directors together Mr. Gerhard Musshafen and Dr. Bruno Oesch (Chairman). Furthermore, Dr. Armin W. Mäder, former CFO of Neurotune assumes the CEO position of Neurotune from Dr. Bruno Oesch who will focus more on strategic as well as business development. These changes will enhance and streamline the management capabilities to achieve Neurotune’s ambitious targets in neuropathic pain and sarcopenia.
Dr. Raimund Eckel joined the board of directors of Neurotune AG. Raimund Eckel studied biology and chemistry at the Universities of Münster and Kiel and received his PhD from the Max Planck Institute in Ploen, Germany. From 1976 through 1999 he ran various international business functions at Boehringer Mannheim, Hoffman-La Roche, Oxochemie and Noxxon pharmaceuticals with operational (Head Medical Marketing & International Product Management, Country President US, Europe and Japan) and strategic responsibilities (Corporate Strategy and Business Development). From 2002 through 2010 he worked as CEO of a management consulting company focused on healthcare before founding his own consulting company, Eckel & Partners Healthcare Consulting in Basel, Switzerland with a specific focus on BD&L and M&A.
Dr. Armin Mäder has several years of experience in banking and biotech companies, and he is also co-founder of a medtech company. He was head of projects for Prosthetics at Institut Straumann AG. Prior to that he was the CFO/COO of the biotech start-up company AC Immune SA in Lausanne, Switzerland where he successfully completed a major financing round as well as a major licensing deal. Armin Mäder started his professional career in the UBS Investment Bank where he has worked in business development, business management and has delivered several time critical multi-million projects and business initiatives. Armin Mäder holds an M.B.A. from IMD in Lausanne and a PhD in Molecular Biology and Biophysics from the ETH Zurich .
Most read news
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Labmodul A/S - Roedovre, Denmark
Evolva to Acquire Abunda Nutrition - Evolva to Gain Fermentation-derived Stevia and Other Next-Generation Nutritional Ingredients
Slim and potent - with side effects - Food supplements for weight loss or enhancing sexual performance can contain illegal active ingredients
EGene Inc. Announces Its Strategic Full-Service Distribution Alliance with AH Diagnostics of Denmark
Global Bioenergies announces break-through in direct biological production of butadiene
DSM receives grant of US Department of Energy for biotechnology research
Norwood_(charity)

Schizophrenia manifests itself in the brain structure - The symptoms of schizophrenia vary greatly from person to person

ImageBiopsy Lab - Wien, Austria
Eppendorf grows faster than the market
La Jolla Institute finds previous seasonal flu infections may provide some level of H1N1 immunity
